anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
MESEMS is a randomised phase 2 trial done at 15 sites in nine countries. Patients (aged 18-50 years) with active relapsing-remitting or progressive multiple sclerosis were included if they had a disease duration of 2-15 years since onset of multiple sclerosis and an Expanded Disability Status Scale score of 2·5-6·5. Patients were randomly assigned (1:1), according to a crossover design, to receive a single intravenous dose of autologous bone marrow-derived MSCs followed by placebo at week 24, or to receive placebo followed by autologous MSCs at week 24, with a follow-up visit at week 48. Primary objectives were to test safety and activity of MSC treatment. The primary safety endpoint was to assess the number and severity of adverse events within each treatment arm. The primary efficacy endpoint was the number of gadolinium-enhancing lesions (GELs) counted over week 4, 12, and 24 compared between treatment groups. The primary efficacy endpoint was assessed in the full analyis set, after all participants completed the week 24 visit. Efficacy endpoints were evaluated using a predefined statistical testing procedure. Safety was monitored throughout the study by recording vital signs and adverse events at each visit.
The invention relates to the medicine, namely to the neurology and may be used for the complex treatment of the degenerative and dystrophic-destructive disorders of the locomotor system. The method for the treatment comprises the deep reflectory muscular massage, the vacuum cups, UHF treatment, and the use of Myorhythm device. In addition, Diprospan is injected under the sacral and pelvic bone. Trental is administered daily intravenously dropwise. Also Actovegin, Pyrocetam, ascorbic acid, and vitamin B6 are injected intravenously. The course of the treatment comprises 10-12 procedures and is repeated in 6-8 months.
Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals. This invention provides hydrogels that degrade to smaller, soluble components in a non-enzymatic process upon exposure to physiological conditions and to methods to prepare them. The hydrogels are prepared from crosslinking agents that undergo elimination reactions under physiological conditions, thus cleaving the crosslinking agent from the backbone of the hydrogel. The invention also relates to the crosslinking agents themselves and intermediates in forming the hydro gels of the invention. The biodegradable hydro gels prepared according to the methods of the invention may be of use in diverse fields, including biomedical engineering, absorbent materials, and as carriers for drug delivery.
Penem carboxyic acid esters of formula (I) are prepd. by esterifying a cpd. of formula (II) or its salt with a cpd. of formula RX in the presence of dimethylaminopyridine of dimethylformamide at 0-70≰C. In the formulas, R is acetoxymethyl, pivaloxymethyl, methoxymethyl, methoxyethoxymethyl, phthalidyl, alpha-ethoxycarbonyloxyethyl, acetamidomethyl or benzamidomethyl group. The derivs. are useful as bactericidal agents.
FIELD: medicine, pharmacy. SUBSTANCE: medicinal form is used by oral route and consists of two phases: phase of nonprolonged releasing and phase of prolonged releasing the components. Form has C 12 -C 24 -fatty acid and pharmaceutically active lipophilic substance. Phase of nonprolonged releasing has part of fatty acid and phase of prolonged releasing has the rest part of fatty acid and at least part of pharmaceutically active substance. Mass ratio of fatty acid and an active substance is from 10:1 to 1:1. C 12 -C 24 -fatty acid is an oleic and/or linolenic acid. Pharmaceutically active lipophilic substance is a propranolol, verapamil, nifedipin, diltiazem, methoprolol, nicardipine and/or labetolol. New medicinal form promotes an absorption redistribution of drug from portal circulatory system to lymphatic system and excludes drug metabolism at its the first passing through the liver. Drug bioavailability is enhanced. EFFECT: enhanced effectiveness of medicinal form. 13 cl, 2 ex
Participants with low grade tumors of any size, or high-grade tumors \< 5 cm that have been (or are expected to be) completely removed by surgery. When the pathologist reviews the tumor specimen, the tissue around the tumor (margins) must be negative for cancer cells, meaning all of the cancer has been removed. These participants will have surgery to remove the tumor, followed by close observation. There will no further therapy after surgery, just monitoring for tumor recurrence and any side effects from surgery.
The invention discloses a traditional Chinese medicament composition for treating dreamed coitus of woman and a preparation method thereof. The traditional Chinese medicament composition is prepared mainly from the following raw material medicines: cicada slough, the root of kudzu vine, mongolian snakegourd root, chrysanthemum, rhizoma phragmitis, jasmine, barbados aloe, Poria cocos, belvedere fruit, lygodium japonicum, pyrrosia lingua, orange peel, dutchmanspipe root, immature bitter orange, agilawood, cyperus rotundus, szechwan chinaberry fruit, spina date seed, silktree albizzia bark, coix seed, magnetite, cinnabar, lily, tuber fleeceflower stem, the shell of abalone, oyster and the like. The traditional Chinese medicament composition can be prepared into any common preparation for oral taking by the conventional method for preparing traditional Chinese medicinal preparation. The traditional Chinese medicament composition can obviously treat dreamed coitus of woman and woman's sexual hyperfunction and symptoms caused by the dreamed coitus of woman and woman's sexual hyperfunction, such as bradypsychia, feeble, chilly, sweating, thin leucorrhea, light-headedness, irritability, mouth parched and throat scorched and the like. The clinic treatment effect of the traditional Chinese medicament composition is exact and remarkable and the effectiveness of the traditional Chinese medicament composition is quick. The traditional Chinese medicament composition also has the advantages of low cist, few toxic or side effect and the like.
It has been established that exposure to cytotoxic doses of HSP90 inhibitor is broadly immunosuppressive, whereas continuous exposure to low-dosages of the same inhibitor exerts anti-tumor activity. The anti-tumor activity is mediated by the host immune system. Compositions and methods for continuous, low-dose exposure to HSP90 inhibitors in combination with one or more immunostimulatory agents for the treatment of cancer are described. Typically, the HSP90 inhibitor is administered in an amount that is between 1% and 20% of the clinically-determined maximum tolerate dose. The immunostimulatory agent can be administered simultaneously with the HSP90 inhibitor, or at some time before or after the HSP90 inhibitor. Compositions including a sub-toxic dose of HSP90 inhibitor in combination with an immunostimulatory agent in an amount effective to treat cancer are also provided.
The invention belongs to the technical field of medicines and discloses an intestinal tract cleaning solution specially used for preoperation of children with hirschsprung disease. The cleaning solution is prepared by using saxoline, 50% magnesium sulfate, hydrogen peroxide, gentamicin and physiological saline as raw materials, respectively proportioning the raw materials according to different characteristics of each medicinal raw material, uniformly blending, separately filling by 100ml/bottle, sealing, sterilizing, and labeling to obtain the cleaning solution. The cleaning solution can fully clean the intestinal tract, greatly shorten the preparation time before the operation of the children with hirschsprung disease, and simultaneously shorten the hospital stays and relieve the family burden of the children with hirschsprung disease. By using the cleaning solution, the physiological saline required for coloclysis in each time can be reduced, the time for coloclysis in each time can be shortened, the mental and physical pain of the children with hirschsprung disease can be relieved, the body consumption of the children with hirschsprung disease can be reduced, and the tolerance to the operation can be improved. The cleaning solution has the advantages of promoting colitis diseases to subside quickly, preventing colitis after the operation, and the like. The intestinal tract cleaning solution disclosed by the invention also has the advantages of simpleness of preparation, convenience for operation, low cost, and easy acceptability to patients. As proved by 120 cases of children with dental ulcer in clinic, the total effective rate of the intestinal tract cleaning solution disclosed by the invention reaches 96%, and no special toxic or side effect is found.
Joint hypermobility syndromes, particularly chronic pain associated with this condition, including Hypermobile Ehlers-Danlos Syndrome (hEDS) and Hypermobility Spectrum Disorders (HSD), present diagnostic challenges due to their multifactorial origins and remain poorly understood from biomechanical and genomic-molecular perspectives. Recent diagnostic guidelines have differentiated hEDS, HSD, and benign joint hypermobility, providing a more objective diagnostic framework. However, incorrect diagnoses and underdiagnoses persist, leading to prolonged journeys for affected individuals. Musculoskeletal manifestations, chronic pain, dysautonomia, and gastrointestinal symptoms illustrate the multifactorial impact of these conditions, affecting both the physical and emotional well-being of affected individuals. Infrared thermography (IRT) emerges as a promising tool for joint assessment, especially in detecting inflammatory processes. Thermal distribution patterns offer valuable insights into joint dysfunctions, although the direct correlation between pain and inflammation remains challenging. The prevalence of neuropathies among hypermobile individuals accentuates the discordance between pain perception and thermographic findings, further complicating diagnosis and management. Despite its potential, the clinical integration of IRT faces challenges, with conflicting evidence hindering its adoption. However, studies demonstrate objective temperature disparities between healthy and diseased joints, especially under dynamic thermography, suggesting its potential utility in clinical practice. Future research focused on refining diagnostic criteria and elucidating the underlying mechanisms of hypermobility syndromes will be essential to improve diagnostic accuracy and enhance patient care in this complex and multidimensional context.
Group 1 Treatment Arm (10 subjects): Zofin + Standard of care (SOC) Ten subjects will receive 1 mL of Zofin on Day 0, Day 4, and Day 8, containing 1-5 x 10\^11 particles/ml. The Zofin dose will be diluted in 100 mL of sterile saline at subject's bedside. In addition to Zofin all subjects in this trial will receive SOC throughout the study period.
Cocaine is a strong central nervous system stimulant that is widely abused throughout the United Sates. Due to its widespread use, it is important to develop an effective treatment for cocaine dependence. Modafinil is a glutamate-enhancing agent. D-amphetamine is a central nervous system stimulant that is approved to treat individuals with narcolepsy and attention deficit disorder. Both modafinil and d-amphetamine may be effective treatments for cocaine dependence. The purpose of this study is to examine the effectiveness of modafinil and d-amphetamine, alone and in combination, in treating cocaine dependent individuals.

This study will last 16 weeks. Participants will be randomly assigned to one of four groups: 1) 60 mg dose of d-amphetamine; 2) 400 mg dose of modafinil; 3) 30 mg dose of d-amphetamine combined with 200 mg dose of modafinil; and 4) placebo. All participants will receive 200 mg of modafinil over 4 days.
Toad venom, a traditional Chinese medicine, exhibits remarkable medicinal properties of significant therapeutic value. The peptides present within toad venom possess a wide range of biological functions, yet the neuropeptide B (NPB) and it modification requires further exploration to comprehensively understand its mechanisms of action and potential applications. In this study, a fusion peptide, ANTP-BgNPB, was designed to possess better analgesic properties through the transdermal modification of BgNPB. After optimizing the conditions, the expression of ANTP-BgNPB was successfully induced. The molecular dynamics simulations suggested that the modified protein exhibited improved stability and receptor binding affinity compared to its unmodified form. The analysis of the active site of ANTP-BgNPB and the verification of mutants revealed that GLN3, SER38, and ARG42 were crucial for the protein's recognition and binding with G protein-coupled receptor 7 (GPR7). Moreover, experiments conducted on mice using the hot plate and acetic acid twist body models demonstrated that ANTP-BgNPB was effective in transdermal analgesia. These findings represent significant progress in the development of transdermal delivery medications and could have a significant impact on pain management.
Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Antihypertensive medication type and dosage will be recorded. Blood and urine samples will be collected at baseline and yearly for three years. All subjects will receive baseline and yearly echocardiograms. Subjects with overweight/obesity (BMI \>=85th percentile for age and sex) will receive baseline and yearly ultrasounds of the liver to evaluate for hepatic fat infiltration. Auscultated, continuous and ambulatory blood pressure will be measured at baseline and yearly.
PURPOSE:To enable exact quantitative determination of an antiimmune complex by using a soln. prepd. by producing and drawing the antibody for other animals, etc. with the agglutinated matter of F(ab')2 fragment of human immune globulin as an antigen and refining the same by dialysis, etc. or the freeze dried matter thereof. CONSTITUTION:Rabbit, etc. are immunized and are let with blood by using, as an antigen, the F(ab')2 fragment prepd. by subjecting the serum, etc. separated from a human blood, etc. for blood transfusion to ammonium sulfate salting out and further fractionating the same with a DEAE cell roll ion exchange chromatography to obtain IgG, etc., and refining the same by pepsin decomposition, etc. Ammonium sulfate is added to such serum and a precipitate is drawn, which is dialyzed with a buffer soln. of 8pH and the fraction passing through a DE-52 column is further refined by a dialysis treatment, etc. to obtain an antibody. The antibody obtd. by freeze drying such antibody or separating the mouth spleen cells obtd. by injecting F(ab')2 thereto, bringing the same into plasmoganny with mouse myeloma P301 and culturing the antibody is used. The specific detection of the immune complex, etc. such as human IgG or the like is thus made possible.
SAR342434 and Humalog will be self-administered subcutaneously via insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion.
The phase Ib study will consist of an accelerated titration, intrapatient dose escalation cohort, with double-dose step design of Verapamil Hydrochloride. Intranasal BID for 1 week. Dose escalation will occur weekly as a doubling of the dose from 10-120mg Verapamil delivered in 240mL buffered normal saline. If a single, any course, dose-limiting toxicity (DLT) or second, any course, IT occurs, two additional patients will be recruited at that identified dose and Phase Ib will revert to a standard 3+3 design. If any patient un-enrolls while the dose escalation is still occurring, they will be replaced to maintain 3 patient cohorts. The maximal administered dose (MAD) will be considered that at which at least 2 DLTs or 4 ITs occur and the MTD will then be assigned to the immediate preceding dose.
PURPOSE: CAR T-cell therapy gives patients new hope, who are diagnosed with relapsed or refractory B-cell lymphoma or B-cell leukaemia. To date, there is no scientific knowledge about the experiences of patients with CAR T-cell therapy, their process of treatment decision making or how they handle potential side effects. The study aims at deepening the understanding of the patient's experiences, indicating how to improve nursing care for this patient population.
METHOD: A qualitative study was carried out. Episodic guideline-based interviews were conducted with 14 patients who had received CAR T-cell therapy. The data analysis was performed according to the Grounded Theory. The study took place at a German university hospital.
RESULTS: Data analysis showed five sequential phases including the following concepts: 'living with cancer recurrence', 'deciding on CAR T-cell therapy', 'waiting for the reinfusion of the CAR T-cells', 'experiencing CAR T-cell therapy' and 'recovering and staying healthy'. The decision for CAR T-cell therapy was characterised by the lack of alternatives and uncertainty about the outcome and side effects.
CONCLUSIONS: Before, during and after CAR T-cell therapy, patients are faced with major challenges for which they need nursing support and guidance. These include preparation for CAR T-cell therapy, handling of side effects and preparation for discharge home.
Participants will receive the flavored water placebo with an additional 150mg of ElevATP (blend of ancient peat and apple extracts). Part of the supplemental intervention.This, and all groups, simultaneously took part in the exercise intervention.
Participants sat on a chair with their left heel resting on the table with the push button switches. participants performed 10 blocks of the aforementioned sequence with their leg, with a 30s break between each block.
The invention relates to a tumour vaccine with a tumour antigen base. In addition to a source of tumour antigens, the vaccine contains a release system for the delayed release of the active agent IFN-.gamma., the active dose of IFN-.gamma. being 50 ng to 5 .mu.g. The IFN-.gamma. is released over a period ranging from several hours to several days. The IFN-.gamma. release system consists preferably of liposomes, and the tumour antigen source preferably of allogenic tumour cells.
Probands are smokers who intend to quit smoking within a clinical conducted smoking cessation program. It is aimed to include 20 persons who stop smoking. Like in the e-cigarette group, a baseline visit at the beginning will measure conventional lung function parameters, mannitol provocation, FeNO and exhaled CO. The measurement will be repeated after 3 months to evaluate changes in these parameters. In addition there will be questionnaires concerning smoking behaviour and health status at the beginning and after 1, 2 and 3 months.
Men with a confirmed diagnosis of IBD between the ages of 40-69 years old. These subjects will have their prostate specific antigen checked via a blood draw during clinic visits over the course of the study period.
The invention discloses a health-care capsule for regulating blood pressure by utilizing sticktight and a preparation method of the health-care capsule. The health-care capsule is prepared from the following traditional Chinese medicine components: 70% to 72% of sticktight, 8% to 10% of wild chrysanthemum, 10% to 12% of schisandra chinensis and 8% to 10% of salvia miltiorrhiza. The preparation method comprises the following steps: extracting, concentrating and drying, preparing soft materials, pelleting, drying, integrating into uniform pellets, sterilizing and packaging so as to obtain the health-care capsule. The health-care capsule has a good function for regulating the blood pressure of a human body. After the health-care capsule is taken by a patient with high blood pressure, the blood pressure can be decreased to reach a normal level; after the health-care capsule is taken by a patient with relatively low blood pressure, the blood pressure can be risen again; the blood pressure is not changed if the health-care capsule is taken by a patient with normal blood pressure. The health-care capsule has certain effects on preventing and treating high blood pressure and cerebral thrombosis. The effective rate of the health-care capsule can reach 100%, and the cure rate of the health-care capsule can reach 98%.
Germline genetic testing for cancer predisposition genes has become an essential component of cancer treatment and risk reduction. The National Comprehensive Cancer Network (NCCN) releases annual genetic testing guidelines that identify characteristics of patients that could be affected by a hereditary cancer syndrome. These guidelines have broadened over time and the implications for past patients of cancer genetics clinics are not well understood. This study is a retrospective chart review aimed at determining the percentage and characteristics of past patients that meet updated NCCN guidelines (Breast, Ovarian, and Pancreas [BOP] v1.2022 and Colorectal [CRC] v1.2021), patients that attended a follow-up appointment, and patients who went on to receive genetic testing. Clinical data and characteristics were compared between the study population as a whole and the cohort of patients that met updated NCCN guidelines BOP v1.2022 and CRC v1.2021. The study population consisted of 280 patients with 76 (27.1%) patients meeting updated NCCN guidelines BOP v1.2022 and CRC v1.2021. The year of initial cancer genetic counseling appointment was statistically significant (p = 0.023) with patients more likely to meet NCCN guidelines BOP v1.2022 and CRC v1.2021 with earlier initial cancer genetic counseling appointments. In the cohort that met updated NCCN guidelines BOP v1.2022 and CRC v1.2021, the most common reason was a change in the NCCN guidelines (BOP or CRC) (54/76, 71.1%) with triple-negative breast cancer diagnosed at any age being the most impactful guideline change (19/54, 35.2%). Twenty-one patients attended a follow-up appointment (7.5%) and of those that received genetic testing (17/21, 81%) most received negative results (13/17, 61.9%), with one pathogenic, low penetrance result (1/17, 5.9%, CHEK2 p.I157T). Provider-initiated follow-up was attributed to most follow-up appointments (16/21, 76.2%) implying patients do not tend to follow-up on their own. Education to non-genetics providers as well as targeted implementation of follow-up protocols possibly managed by genetic counseling assistants and utilizing electronic medical record (EMR) patient messaging could lead to improved patient follow-up.
For the purposes of the study, in the first phase, clinical vignettes will be created, ie short hypothetical scenarios of patients with chronic musculoskeletal pain. The vignettes will feature patients with and without nocipalstic pain. Initially, two experts will evaluate and characterize which vignettes concern patients with nociplastic pain.

Next, a team of physiotherapists with knowledge of chronic pain and CS will evaluate vignettes twice according to the IASP criteria. There will be an interval of 1 month between the two measurements. One month later, the evaluation will be repeated. The investigators will design an Android application "Algo (s) rithm" to enter the questions of the algorithm. In the second phase, Algo (s)rithm app will use to evaluate patients with chronic pain (including patients with fibromyalgia) and healthy. The investigators will compare the result with PPT measurements in the same population.In the present study the inter-rater and test-retest reliability, criterion validity, construct validity will be examined.